C
CDR-Life
A biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics based on its proprietary antibody-based T cell engager technology
About CDR-Life
CDR-Life is a biotech startup that specializes in developing innovative immunotherapies for cancer treatment. The company's unique M-gager® technology creates antibody-based T cell engagers that target tumor-specific antigens with high precision. In simpler terms, they are developing a new type of cancer treatment that uses the body's immune system to fight cancer cells.
The company's primary market is the healthcare and pharmaceutical industry, specifically those dealing with cancer treatment. Their clients would primarily be healthcare providers and potentially other pharmaceutical companies interested in their technology.
CDR-Life operates on a business model that involves the discovery, development, and commercialization of their immunotherapies. They generate revenue through the sale of these therapies once they have been approved for use. Additionally, they may also earn income through partnerships with other pharmaceutical companies that wish to use their technology.
Founded in 2017 by a team of experienced drug developers and biotech entrepreneurs, CDR-Life has a strong focus on innovation and the development of superior T cell engaging therapies. The team's broad expertise in antibody discovery, pharmacology, clinical and drug product development positions the company well for breaking new ground in cancer treatment.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Zurich, Switzerland
- Employees
- 72
- Open positions
- None listed
- Dealroom signal
- 75.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Apr 2022 | $76M | $304M | RA Capital Management · Jeito Capital · Omega Funds | ↗ |
| SUPPORT PROGRAMOther financing | Dec 2017 | $0 | — | Grow Cluster Wädenswil | — |
Growth signals
Latest recorded traffic for CDR-Life is 9.4K monthly website visits, up 1.1% over the last three months. CDR-Life's team grew 4.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
RA Capital Management
Jeito Capital
Omega Funds
Other known investors1 additional known investor
Grow Cluster Wädenswil
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CDR-Life on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CDR-Life’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.